Moors & Cabot Inc. Sells 190 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Moors & Cabot Inc. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.5% in the 3rd quarter, HoldingsChannel reports. The firm owned 1,805 shares of the medical research company’s stock after selling 190 shares during the quarter. Moors & Cabot Inc.’s holdings in Charles River Laboratories International were worth $356,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of CRL. O Shaughnessy Asset Management LLC bought a new position in Charles River Laboratories International in the first quarter valued at approximately $415,000. CreativeOne Wealth LLC bought a new position in shares of Charles River Laboratories International in the 1st quarter valued at $201,000. Axxcess Wealth Management LLC raised its holdings in shares of Charles River Laboratories International by 54.8% during the 1st quarter. Axxcess Wealth Management LLC now owns 2,094 shares of the medical research company’s stock worth $567,000 after buying an additional 741 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Charles River Laboratories International by 50.4% during the 1st quarter. Advisors Asset Management Inc. now owns 3,359 shares of the medical research company’s stock worth $910,000 after buying an additional 1,126 shares during the last quarter. Finally, Toronto Dominion Bank boosted its stake in Charles River Laboratories International by 2.1% in the first quarter. Toronto Dominion Bank now owns 29,032 shares of the medical research company’s stock valued at $7,866,000 after buying an additional 606 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

Shares of NYSE CRL opened at $195.77 on Friday. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The firm’s 50-day moving average price is $194.99 and its 200-day moving average price is $205.86. The firm has a market capitalization of $10.01 billion, a P/E ratio of 24.50, a P/E/G ratio of 5.01 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1-year low of $176.48 and a 1-year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $975.99 million. During the same quarter last year, the firm posted $2.72 earnings per share. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities research analysts anticipate that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has approved a share buyback plan on Wednesday, August 7th that allows the company to buyback $1.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

CRL has been the subject of several research analyst reports. Baird R W downgraded Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 8th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. The Goldman Sachs Group lowered their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a report on Thursday, August 8th. CLSA downgraded Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a report on Monday, November 18th. Finally, Redburn Atlantic began coverage on Charles River Laboratories International in a research note on Monday, October 14th. They set a “sell” rating and a $151.00 price target on the stock. Three research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, Charles River Laboratories International currently has an average rating of “Hold” and an average price target of $214.38.

Insiders Place Their Bets

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the sale, the director now directly owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).